THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 126 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,699,157 | +47.1% | 151,440 | +33.0% | 0.01% | +66.7% |
| Q3 2022 | $1,155,000 | +40.7% | 113,867 | +25.7% | 0.01% | +20.0% |
| Q2 2022 | $821,000 | -44.4% | 90,569 | -41.4% | 0.01% | -58.3% |
| Q1 2022 | $1,477,000 | +59.5% | 154,485 | +84.3% | 0.01% | +33.3% |
| Q4 2021 | $926,000 | +379.8% | 83,822 | +221.4% | 0.01% | +350.0% |
| Q3 2021 | $193,000 | +1.6% | 26,084 | +144.0% | 0.00% | -33.3% |
| Q4 2020 | $190,000 | -70.5% | 10,689 | -65.2% | 0.00% | -72.7% |
| Q2 2020 | $645,000 | -10.4% | 30,751 | +10.6% | 0.01% | -15.4% |
| Q4 2019 | $720,000 | +52.2% | 27,809 | -4.0% | 0.01% | +44.4% |
| Q2 2019 | $473,000 | +56.6% | 28,969 | +117.1% | 0.01% | -10.0% |
| Q1 2019 | $302,000 | +50.2% | 13,342 | +69.8% | 0.01% | +11.1% |
| Q4 2018 | $201,000 | +570.0% | 7,858 | +744.0% | 0.01% | +350.0% |
| Q4 2016 | $30,000 | – | 931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |